50% off Premium Yearly
Cineplex IncCGX.TOBUYMay 12, 2014Stock price when the opinion was issued
As of Jun 19, 2026. Market Open.
Revenue growth is coming back a bit, with lower comparables from last year helping the year-over-year figures. Its debt levels are high, with net debt of $1.9B, and a net debt/EBITDA of 6.8X. Interest costs are $137M (last 12 months) and these will likely rise a bit with higher rates. 12-month cash flow was $116M and therein lies the problem. The debt is mostly due in the next five years. With attendance back, and a decent film slate, bankruptcy is becoming less of a concern, but it is still hard to paint a really positive picture here because of the leverage.
It is somewhat cheap (0.4X forward sales), but also has a fairly high forward P/E of 20.2X. It could become a takeover target, however, we would not place a high level of probability on that at these current levels.
Unlock Premium - Try 5i Free
Cineplex remains a recovery story, and its beta of 2.88 signals more risk than usual. It rose 10% in Q1, but the chart was choppy. So, consider Cineplex a partial buy. After all, Covid didn’t kill cinema-going, as some expected, but deferred it. We still love the big screen. Read Dark horses: Nuvei, Cineplex, Boralex for our full analysis.
Had some high expenses from some recent acquisitions. Very well managed company. Theatre business is a very stagnant one these days, but this company has been very proactive in adding revenue streams that are not traditional such as hockey games, Opera, more concession revenues, advertising, etc. Trading at a pretty high multiple, but justifiably so. Pullbacks are an opportunity for you to Buy. Decent dividend of 3.6%.